Related Experiment Video
Updated: Sep 23, 2025
Preparing a 68Ga-labeled Arginine Glycine Aspartate RGD-peptide for Angiogenesis
Published on: January 7, 2019
The Current Role of Peptide Receptor Radionuclide Therapy in Meningiomas
Christina-Katharina Fodi1,2, Jens Schittenhelm2,3, Jürgen Honegger1,2
1Department of Neurosurgery and Neurotechnology, University Hospital Tübingen, Eberhard-Karls University, 72076 Tübingen, Germany.
Abstract:
Meningiomas are the most common primary intracranial tumors. The majority of patients can be cured by surgery, or tumor growth can be stabilized by radiation. However, the management of recurrent and more aggressive tumors remains difficult because no established alternative treatment options exist. Therefore, innovative therapeutic approaches are needed. Studies have shown that meningiomas express somatostatin receptors. It is well known from treating neuroendocrine tumors that peptide radioreceptor therapy that targets somatostatin receptors can be effective. As yet, this therapy has been used for treating meningiomas only within individual curative trials. However, small case series and studies have demonstrated stabilization of the disease. Therefore, we see potential for optimizing this therapeutic option through the development of new substances and specific adaptations to the different meningioma subtypes. The current review provides an overview of this topic.
Insights
Peptide radioreceptor therapy targeting somatostatin receptors shows promise for treating aggressive meningiomas. Further research into new substances and subtype adaptations could optimize this innovative treatment option.
Area of Science:
- Neuro-oncology
- Nuclear medicine
- Radiopharmacology
Background:
- Meningiomas are common primary brain tumors, often treatable with surgery or radiation.
- Recurrent and aggressive meningiomas lack effective alternative treatments, necessitating novel therapeutic strategies.
- Meningiomas express somatostatin receptors, a target for peptide radioreceptor therapy.
Purpose of the Study:
- To review the potential of peptide radioreceptor therapy for meningioma management.
- To explore the optimization of somatostatin receptor-targeted therapies for meningiomas.
- To discuss the development of new radiopharmaceuticals and subtype-specific adaptations.
Main Methods:
- Review of existing literature on somatostatin receptor expression in meningiomas.
- Analysis of data from individual curative trials and small case series using peptide radioreceptor therapy.
- Exploration of therapeutic strategies for neuroendocrine tumors as a model.
Main Results:
- Peptide radioreceptor therapy has demonstrated disease stabilization in meningioma patients.
- Individual trials and case series suggest potential efficacy, though not yet a standard treatment.
- Somatostatin receptor targeting is a viable therapeutic avenue for meningiomas.
Conclusions:
- Peptide radioreceptor therapy targeting somatostatin receptors offers a promising avenue for managing difficult meningiomas.
- Further development of novel radiopharmaceuticals and tailored approaches for meningioma subtypes is warranted.
- This therapeutic strategy holds potential for improving outcomes in recurrent or aggressive meningioma cases.
